Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Shuichi Fujioka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6388-0717; OpenAlex author ID A5031736405, A5043750787. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 12

  1. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  2. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  3. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  4. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  5. Usefulness of the mesopancreas-first approach using isolating tape in conversion surgery for pancreatic cancer. First author DOI 10.1016/j.suronc.2022.101850↗
  6. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08911-4↗
  7. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. Co-author DOI 10.1080/07357907.2019.1661427↗
  8. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.8961↗
  9. Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.6071↗
  10. Isolating tape method is useful for an early judgment of curability during pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.381↗
  11. Histopathologically proven autoimmune pancreatitis mimicking neuroendocrine tumor or pancreatic cancer. Co-author DOI 10.1159/000336199↗
  12. Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel. Co-author PMID 23155247↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 5 shared papers, 2022–2025 · strength 0.92
  2. Masashi Tsunematsu · 4 shared papers, 2022–2025 · strength 0.70
  3. Koichiro Haruki · 4 shared papers, 2022–2025 · strength 0.70
  4. Yoshihiro Shirai · 4 shared papers, 2022–2025 · strength 0.70
  5. Takeshi Gocho · 4 shared papers, 2022–2025 · strength 0.70
  6. Ryoga Hamura · 4 shared papers, 2022–2025 · strength 0.70
  7. Kenei Furukawa · 3 shared papers, 2022–2025 · strength 0.54
  8. Kyohei Abe · 2 shared papers, 2023–2025 · strength 0.40
  9. Hironori Shiozaki · 2 shared papers, 2022–2023 · strength 0.38
  10. Shinji Onda · 4 shared papers, 2012–2023 · strength 0.36
  11. Zensho Ito · 4 shared papers, 2017–2021 · strength 0.32
  12. Shigeo Koido · 4 shared papers, 2017–2021 · strength 0.32
  13. Tadashi Uwagawa · 2 shared papers, 2022–2023 · strength 0.29
  14. Masayuki Saruta · 3 shared papers, 2018–2021 · strength 0.25
  15. Haruo Sugiyama · 3 shared papers, 2018–2021 · strength 0.25
  16. Shin Kan · 2 shared papers, 2019–2021 · strength 0.19
  17. Toshifumi Ohkusa · 2 shared papers, 2017–2021 · strength 0.17
  18. Katsuhiko K. Yanaga · 3 shared papers, 2012–2016 · strength 0.16
  19. Michinori Matsumoto · 1 shared paper, 2023 · strength 0.16
  20. Taro Sakamoto · 1 shared paper, 2023 · strength 0.16
  21. Masato Okamoto · 2 shared papers, 2018–2019 · strength 0.15
  22. Yuki Fujiwara · 1 shared paper, 2022 · strength 0.13
  23. Hiroaki Shiba · 1 shared paper, 2022 · strength 0.13
  24. Tomoya Kanai · 2 shared papers, 2017–2018 · strength 0.13
  25. Mikio Kajihara · 2 shared papers, 2017–2018 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.